Vecuronium Uses, Dosage, Side Effects & Safety | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Vecuronium
Therapeutic Class: Neuromuscular Blocking Agent
Subclass: Non-depolarising Aminosteroid Muscle Relaxant
Specialty: Anaesthesiology
Schedule (India): Schedule H
Route(s): Intravenous (IV)
Formulations Available in India:
- Vecuronium bromide injection: 4 mg vial (lyophilised powder for reconstitution)
- Vecuronium bromide injection: 10 mg vial (lyophilised powder for reconstitution)
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
▶️ Skeletal Muscle Relaxation during General Anaesthesia (including endotracheal intubation)
| Parameter | Details |
|
Starting dose (Intubation)
|
0.08–0.1 mg/kg IV bolus |
|
Titration
|
Guided by neuromuscular monitoring (train-of-four) |
|
Usual maintenance dose
|
0.01–0.015 mg/kg IV bolus every 20–40 minutes OR continuous infusion at 1–2 mcg/kg/min |
|
Maximum dose
|
Titrate to clinical response; no fixed maximum—guided by neuromuscular monitoring |
|
Onset
|
2–3 minutes |
|
Duration of action
|
20–40 minutes (single intubating dose) |
Clinical Notes:
- For routine intubation, onset is slower compared to succinylcholine
- Adequate anaesthesia and sedation must be ensured before administration
- Always have resuscitation equipment and mechanical ventilation available
▶️ Rapid Sequence Intubation (when succinylcholine is contraindicated)
| Parameter | Details |
|
Starting dose
|
0.15 mg/kg IV bolus |
|
Titration
|
Not applicable for RSI |
|
Maintenance dose
|
As per standard surgical dosing above |
|
Maximum dose
|
Single bolus as stated |
|
Onset
|
60–90 seconds at higher dose |
Clinical Notes:
- Reserved for situations where succinylcholine is contraindicated (burns, hyperkalaemia risk, denervation injuries, prolonged immobility)
- Longer onset than succinylcholine—preoxygenation is critical
Secondary Indications — Adults (Off-label, if any)
▶️ Facilitation of Mechanical Ventilation in ICU
| Parameter | Details |
|
Starting dose
|
0.08–0.1 mg/kg IV bolus |
|
Titration
|
Based on train-of-four (TOF) monitoring; target 1–2 twitches |
|
Usual maintenance dose
|
0.8–1.7 mcg/kg/min continuous IV infusion |
|
Maximum dose
|
Titrate to effect; no fixed ceiling |
|
Duration
|
Shortest possible duration; daily sedation holidays and reassessment recommended |
- OFF-LABEL
- Specialist only — Critical care specialist supervision mandatory
- Evidence basis: Supported by international ICU guidelines; widely used in Indian tertiary ICU practice
- Important: Concurrent adequate sedation and analgesia mandatory; drug does not provide sedation or analgesia
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
▶️ Muscle Relaxation for Intubation and Surgical Anaesthesia
| Age Group | Intubation Dose | Maintenance Dose | Clinical Notes |
|
Neonates (<1 month)
|
Use with extreme caution; only under paediatric anaesthesiologist | Avoid unless specialist input | Prolonged and unpredictable effect due to immature hepatic metabolism |
|
Infants (1–12 months)
|
0.08–0.1 mg/kg IV bolus | 0.01–0.015 mg/kg IV every 25–30 min | Recovery slower than in older children; neuromuscular monitoring essential |
|
Children (≥1 year)
|
0.08–0.1 mg/kg IV bolus | 0.01 mg/kg IV every 15–30 min OR 1–2 mcg/kg/min continuous IV infusion | Neuromuscular monitoring recommended |
Minimum age: Not recommended in neonates (<1 month) except under paediatric anaesthesiologist supervision due to unpredictable pharmacokinetics.
Safety monitoring:
- Continuous neuromuscular transmission monitoring mandatory
- Temperature monitoring (hypothermia prolongs action)
- Ensure adequate ventilatory support throughout
Secondary Indications — Paediatrics (Off-label, if any)
▶️ ICU Paralysis for Mechanical Ventilation
- Indication: Facilitation of mechanical ventilation in paediatric ICU
- Dose: Same as surgical dosing; continuous IV infusion with close TOF monitoring
- Duration: Shortest effective duration; daily interruption to assess recovery
- OFF-LABEL
- Specialist only — Paediatric intensivist supervision mandatory
- Evidence basis: Extrapolated from adult ICU practice and paediatric critical care protocols
- Not recommended in neonates except under specialist supervision
RENAL ADJUSTMENT
| Renal Function | Recommendation |
|
Mild–Moderate impairment
|
No routine dose adjustment; monitor duration of effect |
|
Severe impairment / Anuric patients
|
Prolonged duration possible; reduce dose and titrate using neuromuscular monitoring |
|
Intermittent haemodialysis
|
Not significantly dialysed; use with caution and monitor |
|
Continuous renal replacement therapy
|
Use with careful titration; neuromuscular monitoring essential |
HEPATIC ADJUSTMENT
| Hepatic Function | Recommendation |
|
Mild impairment
|
Initiate at usual dose; titrate carefully based on response |
|
Moderate impairment
|
Prolonged duration expected; reduce dose by 25–50% and extend dosing intervals |
|
Severe impairment
|
Avoid if possible; use only under specialist supervision with intensive neuromuscular monitoring |
CONTRAINDICATIONS
- Known hypersensitivity to vecuronium bromide or other aminosteroid neuromuscular blocking agents
- Inability to provide adequate mechanical ventilation support
- Known hypersensitivity to bromide compounds
CAUTIONS
- Patients with neuromuscular disorders (myasthenia gravis, Lambert-Eaton syndrome) — extreme sensitivity; reduce dose significantly
- Electrolyte abnormalities (hypokalaemia, hypocalcaemia, hypermagnesaemia) — potentiate blockade
- Hepatic impairment — prolonged effect
- Renal impairment — may prolong recovery
- Elderly patients — increased sensitivity and delayed recovery
- Critically ill patients — higher risk of prolonged weakness
- Patients with burns or denervation injuries — resistance may develop; higher doses required
- Hypothermia — prolongs action
- Acidosis — prolongs action
- History of malignant hyperthermia — use with caution; not a primary trigger but caution warranted
- Ensure reversal agents (neostigmine + glycopyrrolate) are available
PREGNANCY
| Parameter | Details |
|
Risk category
|
No formal Indian category; limited human data but no evidence of teratogenicity with short-term procedural use |
|
Use in pregnancy
|
May be used when benefit outweighs risk; commonly used during caesarean section under general anaesthesia |
|
Preferred alternatives
|
Succinylcholine preferred for rapid sequence induction in obstetric anaesthesia |
|
Monitoring
|
Monitor maternal oxygenation, ventilation, and uterine tone; ensure adequate ventilatory support post-procedure |
LACTATION
| Parameter | Details |
|
Compatibility
|
Compatible with breastfeeding |
|
Drug levels in milk
|
Negligible with single procedural use |
|
Resumption of breastfeeding
|
May resume once mother is fully conscious and alert |
|
Infant monitoring
|
Not necessary for short procedural use |
ELDERLY
- Recommended starting dose: Lower end of range (0.08 mg/kg)
- Titration: Slower titration; allow longer intervals between doses
- Additional risks: Prolonged recovery, delayed respiratory function return, increased sensitivity
- Monitoring: Mandatory neuromuscular monitoring; ensure complete recovery before extubation
- Reversal: May require longer time for adequate reversal; verify TOF ratio >0.9 before extubation
MAJOR DRUG INTERACTIONS
| Interacting Drug | Effect | Management |
|
Aminoglycosides (gentamicin, amikacin, streptomycin)
|
Potentiate neuromuscular blockade; prolonged paralysis | Avoid concurrent use if possible; if unavoidable, reduce vecuronium dose and monitor closely |
|
Magnesium sulphate
|
Enhances neuromuscular blockade significantly | Critical in pre-eclampsia/eclampsia patients; reduce dose substantially and monitor |
|
Succinylcholine
|
Additive or prolonged paralysis when used sequentially | Allow recovery from succinylcholine before vecuronium; reduce vecuronium dose if given after |
|
Inhalational anaesthetics (isoflurane, sevoflurane, desflurane)
|
Potentiate neuromuscular blockade | Reduce vecuronium dose by 25–40% during inhalational anaesthesia |
|
Clindamycin, lincomycin
|
Potentiate neuromuscular blockade | Monitor closely; may require dose reduction |
MODERATE DRUG INTERACTIONS
| Interacting Drug | Effect | Management |
|
Loop diuretics / Thiazides
|
Electrolyte shifts (hypokalaemia) may enhance blockade | Correct electrolytes before use; monitor |
|
Phenytoin / Carbamazepine (chronic use)
|
Resistance to vecuronium; reduced efficacy | May require higher doses; titrate to effect |
|
Lithium
|
May prolong neuromuscular blockade | Monitor closely; may require dose reduction |
|
Calcium channel blockers
|
May enhance duration of action | Monitor neuromuscular function |
|
Quinidine, procainamide
|
Potentiate neuromuscular blockade | Monitor ECG and neuromuscular function |
|
Corticosteroids (chronic use)
|
May alter neuromuscular response; risk of ICU-acquired weakness with combined prolonged use | Limit duration; monitor for weakness |
COMMON ADVERSE EFFECTS
- Skeletal muscle weakness (expected pharmacological effect)
- Prolonged neuromuscular blockade (dose-dependent)
- Injection site reactions (minor)
SERIOUS ADVERSE EFFECTS
- Anaphylaxis / Anaphylactoid reactions — rare but potentially fatal; immediate resuscitation required
- Prolonged paralysis — requiring extended mechanical ventilation
- Respiratory arrest — if ventilatory support not adequate
- Residual postoperative weakness — risk of aspiration, respiratory compromise
- ICU-acquired weakness / Critical illness myopathy — with prolonged use in ICU
- Bronchospasm — rare
MONITORING REQUIREMENTS
| Timing | Parameters |
|
Baseline
|
Electrolytes (K⁺, Ca²⁺, Mg²⁺), renal function, hepatic function (if prolonged use anticipated) |
|
During use
|
Continuous neuromuscular monitoring (train-of-four / peripheral nerve stimulator); vital signs; ventilatory parameters |
|
Before extubation
|
Ensure TOF ratio ≥0.9; clinical assessment of muscle strength (head lift, grip strength) |
|
Long-term ICU use
|
Daily interruption of paralysis to assess recovery; watch for signs of critical illness myopathy |
BRANDS AVAILABLE IN INDIA
- Norcuron (MSD/Organon)
- Vecuron
- Wecuron
- Vecton
- Vecuronium BP (generic formulations)
Available as single-drug lyophilised vials; no major fixed-dose combinations
PRICE RANGE (INR)
| Formulation | Approximate Price |
| Vecuronium 4 mg vial | ₹25–₹50 |
| Vecuronium 10 mg vial | ₹40–₹90 |
- NPPA price-controlled under NLEM 2022
- Lower pricing available through government supply channels (AIIMS, state hospitals, CGHS)
CLINICAL PEARLS
- Always use neuromuscular monitoring — clinical assessment alone is inadequate; train-of-four monitoring prevents over- or under-dosing
- Do not administer without ventilatory support — complete paralysis including respiratory muscles occurs
- Reversal timing is critical — administer neostigmine + glycopyrrolate only when TOF shows ≥2 twitches; verify TOF ratio ≥0.9 before extubation
- Haemodynamically stable agent — lacks significant histamine release and vagolytic effects; preferred in cardiac patients
- Duration prolonged in liver disease — vecuronium is primarily hepatically metabolised; use lower doses and extended intervals
- Not an analgesic or sedative — always ensure adequate anaesthesia/sedation; paralysed patients can be aware
TAGS
vecuronium; neuromuscular blocking agent; NMBA; aminosteroid; anaesthesia; intubation; muscle relaxant; ICU paralysis; NLEM India; Schedule H
VERSION
RxIndia v1.0 — 03 Feb 2026
REFERENCES
- CDSCO-approved prescribing information
- Indian Pharmacopoeia
- NLEM 2022
- AIIMS Anaesthesia protocols
- API Textbook of Medicine
- ICMR Critical Care protocols
- Goodman & Gilman’s Pharmacological Basis of Therapeutics (class reference)
- International ICU sedation guidelines (supportive, off-label use noted)
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.